NEW YORK (360Dx) – When Abhi Gholap now thinks about a company that he sold to Roche in 2010 for $100 million, he sees that the market may not have been quite ready for digital pathology at the time.

But seven years after selling that company called BioImagene, the space has evolved and where healthcare professionals once weren't quite sure about the advantages of using digital pathology technology, Gholap now sees an opportunity for on-demand, cloud-based digital services, he said in an interview.